Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics.
Mantle cell lymphoma (MCL) is a well-defined lymphoid malignancy characterized by a rapid clinical evolution and poor response to current therapeutic protocols. The genetic and molecular mechanisms involved in its pathogenesis combine the dysregulation of cell proliferation and survival pathways with a high level of chromosome instability that seems related to the disruption of the DNA damage response pathway. Understanding these mechanisms and how they affect tumour behaviour is providing the rationale for the identification of reliable predictors of clinical evolution and the design of innovative therapeutic strategies that could open new avenues for the treatment of patients with MCL.
Jares
Pedro
P
Haematopathology Section, Laboratory of Pathology, and Genomics Unit, Hospital Clinic, Institut de Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain.
Colomer
Dolors
D
Campo
Elias
E
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects; D001402:B-Lymphocytes / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D002454:Cell Differentiation / Q000235:genetics; D002470:Cell Survival / Q000187:drug effects / Q000235:genetics; D056741:Cyclin D; D019938:Cyclin D1 / Q000235:genetics / Q000378:metabolism; D016213:Cyclins / Q000235:genetics; D004249:DNA Damage / Q000235:genetics; D016503:Drug Delivery Systems / Q000379:methods*; D004341:Drug Evaluation; D015870:Gene Expression; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D061988:Proteasome Inhibitors; D011519:Proto-Oncogenes; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D056741:Cyclin D; D016213:Cyclins; D061988:Proteasome Inhibitors; D019938:Cyclin D1